Other Events ·
Lakefront Biotherapeutics NV received a transparency notification from Bank of America Corporation indicating that the…
GLPGFLakefront Biotherapeutics NV
Lakefront Biotherapeutics NV received a transparency notification from Bank of America Corporation indicating that the financial institution crossed the 10% voting rights threshold in the company on August 18, 2026. As of August 19, 2026, Bank of America and its affiliates held 1,419,144 direct voting rights and 5,243,453 equivalent financial instruments, representing a total of 10.11% of the company's 65,897,071 outstanding shares. The position includes significant holdings in swaps and rights to use securities across various expiration dates through 2028. Lakefront Biotherapeutics is a biotechnology company developing clinical-stage medicines for immunology and inflammation.